Royalty Table

Royalties from other partnered products not listed are either single or double digit royalties as described under collaborative research and development programs in the current 10-K. Not all royalties are disclosed due to confidentiality requirements.

 

 

Eltrombopag (PROMACTA®)(1)(2)                    
4.7% 
6.6% 
7.5% 
9.4% 
9.3%
Less than $100M annual sales
Sales in range of $100M - $200M 
Sales in range of $200M - $400M 
Sales greater than $400M 
Sales greater than $1.5B
GSK-5921(2) 14.5%All sales (6.5% for first year sales)
Carfilzomib (KYPROLIS®)(1)Onyx

1.5% 
2.0% 
2.5% 
3.0%

Sales up to and including $250M 
Sales in range of $251M - $500M 
Sales in range of $501M - $750M 
Sales greater than $750M

AVINZA® (1) 5%If sales are less than $200M annually 
Higher royalties paid if sales exceed $200M
Bazedoxifene (VIVIANT™)(1)
BZA/CE (DUAVEE™)


 0.5% 
1.5% 
2.5%
Less than $400M annual sales 
Sales in range of $400M - $1.0B annually 
Sales greater than $1B annually 
Sparsentan Retrophin9%All sales

 

(1)

 Currently receiving royalty payments

(2)

 Net of payments due to The Rockefeller University.

 

 

 

 

 

Royalty Table

Royalties from other partnered products not listed are either single or double digit royalties as described under collaborative research and development programs in the current 10-K. Not all royalties are disclosed due to confidentiality requirements.

 

 

Eltrombopag (PROMACTA®)(1)(2)                    
4.7% 
6.6% 
7.5% 
9.4% 
9.3%
Less than $100M annual sales
Sales in range of $100M - $200M 
Sales in range of $200M - $400M 
Sales greater than $400M 
Sales greater than $1.5B
GSK-5921(2) 14.5%All sales (6.5% for first year sales)
Carfilzomib (KYPROLIS®)(1)Onyx

1.5% 
2.0% 
2.5% 
3.0%

Sales up to and including $250M 
Sales in range of $251M - $500M 
Sales in range of $501M - $750M 
Sales greater than $750M

AVINZA® (1) 5%If sales are less than $200M annually 
Higher royalties paid if sales exceed $200M
Bazedoxifene (VIVIANT™)(1)
BZA/CE (DUAVEE™)


 0.5% 
1.5% 
2.5%
Less than $400M annual sales 
Sales in range of $400M - $1.0B annually 
Sales greater than $1B annually 
Sparsentan Retrophin9%All sales

 

(1)

 Currently receiving royalty payments

(2)

 Net of payments due to The Rockefeller University.